Regeneron Expects Earnings Hit After $24 Million R&D Charge
By Don Nico Forbes
Regeneron Pharmaceuticals expects to incur an acquired in-process research and development charge of about $24 million in the second quarter, which should negatively impact earnings per share.
The biotechnology company said the charge will likely hit net income per diluted share for the quarter by roughly 18 cents.
Regeneron said the charge relates to up-front payments, as well as a premium on equity securities purchased, in connection with collaboration and licensing agreements.
Write to Don Nico Forbes at don.forbes@wsj.com
(END) Dow Jones Newswires
July 08, 2024 08:00 ET (12:00 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
3 Dividend Stocks for October 2024
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued